From: Plasma neurofilament light chain and glial fibrillary acidic protein predict stroke in CADASIL
 | No stroke (n = 16) | IS only (n = 26) | Ever ICH (n = 21) | p value |
---|---|---|---|---|
Age (years) | 56.1 ± 9.2 | 59.0 ± 9.4 | 60.7 ± 9.3 | 0.22 |
Sex | 11 (68.8%) | 15 (57.7%) | 14 (66.7%) | 0.72 |
Hypertension | 3 (18.8%) | 14 (53.9%) | 17 (81.0%) | 0.001 |
Diabetes mellitus | 3 (18.8%) | 9 (34.6%) | 3 (14.3%) | 0.25 |
Hyperlipidemia | 7 (43.8%) | 9 (34.6%) | 9 (42.9%) | 0.79 |
Ever smoking | 3 (18.8%) | 8 (30.8%) | 8 (38.1%) | 0.47 |
Headache | 4 (25.0%) | 2 (15.4%) | 1 (7.1%) | 0.45 |
Plasma biomarkers | ||||
NfL | 2.53 ± 0.90 | 3.49 ± 1.38 | 3.46 ±1.24 | 0.03 |
GFAP | 4.42 ± 0.40 | 4.95 ± 1.31 | 5.89 ± 1.66 | 0.01 |
Tau | − 0.74 ± 1.17 | − 0.21 ± 1.11 | − 0.15 ± 1.34 | 0.29 |
UCHL1 | 2.16 ± 0.73 | 2.40 ± 1.24 | 3.07 ± 1.66 | 0.07 |
Neuroimaging markers | ||||
WMH* | 2.2 ± 1.0 | 2.0 ± 0.9 | 2.8 ± 0.3 | 0.04 |
Number of lacunes* | 3.8 ± 4.3 | 6.2 ± 5.4 | 4.7 ± 4.6 | 0.30 |
Number of CMBs†| 15.0 ± 32.2 | 14.5 ± 19.7 | 32.2 ± 29.3 | 0.02 |
Location of CMBs none/lobar/deep/mixed | 5/1/2/6 | 5/0/7/9 | 0/0/1/12 | 0.02 |
Follow-up | ||||
Total duration (years) | 2.11 ± 0.31 | 3.20 ± 1.62 | 3.78 ± 2.73 | 0.09 |
Recurrent stroke | 0 (0%) | 3 (11.5%) | 7 (33.3%) | 0.02 |